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Available online 8 August 2006Abstract—HIV-1 infection of the brain and PAF neurotoxicity are implicated in AIDS dementia complex. We previously reported
that a trisubstituted piperazine derivative is able to diminish both HIV-1 replication in monocyte-derived macrophages and PAF-
induced platelet aggregation. We report in this work new compounds obtained by modifying its piperazine substituents. The struc-
ture–activity relationship study shows that a better dual activity or even pure antiretroviral compounds can be obtained in this
series.
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Human immunodeﬁciency virus type 1 (HIV-1) infec-
tion rapidly results in the invasion of the central nervous
system (CNS) by the virus and in neurologic diseases in
a large part of the infected population. HIV-associated
dementia (HAD), including memory impairments and
psychomotor slowing, occurs after HIV infection of
the CNS and aﬀected 15–20% of adults and 50% of chil-
dren during the later stages of the disease.1,2 The intro-
duction of the highly active antiretroviral therapy
enables HAD incidence to decline to 8–10%.3,4 HIV-
infected and activated brain-resident macrophages and0968-0896/$ - see front matter  2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2006.07.031
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* Corresponding author. Tel.: +33 1 4427 5594; fax: +33 1 4427
5641; e-mail: serradji@paris7.jussieu.frmicroglia, the main cellular targets of the virus in the
CNS, seem to be the responsible cells for the inﬂamma-
tory processes induced since the neurons do not appear
to be infected by HIV-1 and neuronal death can occur
soon after exposure to HIV-1-infected monocyte culture
ﬂuids.5–7 These data support the concept that the path-
ogenesis of HIV-associated dementia is likely due to
indirect eﬀects of HIV infection of the brain, possibly
through the secretion of soluble factors by macrophages
and microglia. Monocyte production of neurotoxic
factors seems to require HIV-1 infection, monocyte acti-
vation and astroglia and/or neuronal monocyte interac-
tions.6,8,9 The proinﬂammatory cytokine TNF-a and the
phospholipid mediator platelet-activating factor (PAF)
are such factors and their secretion has been shown to
be enhanced in HIV-1-infected monocytes after a cell
activation by antigenic stimuli in vitro or contact with
8110 N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125neural cells in vivo.9 Moreover, high levels of PAF are
detected in the cerebrospinal ﬂuid (CSF) of HIV-1-
infected patients with immunosuppression and signs of
CNS dysfunctions.10 When applied to primary neuronal
foetal cultures at concentrations close to those found in
the CSF of HIV-infected patients, PAF induces a dose-
dependent neurotoxicity which can be blocked by the
PAF-antagonist WEB 2086, the N-methyl-D-aspartate
receptor antagonist, MK-801, or by PAF-acetylhydro-
lase (PAF-AH), the catabolic enzyme of PAF.10,11 These
results suggest that PAF is likely an HIV-1-induced neu-
rotoxin which plays a critical role in the course of HIV-
dementia and provide this mediator as a putative thera-
peutic target in this pathology.
We have previously shown that the compound 1a12
(PMS 601, Fig. 1), a piperazine derivative bearing a car-
bamate function on a carbon of the cycle and two 3,4,5-
trimethoxybenzoyl substituents on the nitrogens, is able
to inhibit HIV-1 replication in monocyte-derived macro-
phages (MDM) infected with the reference macrophage-
tropic strain HIV-1/Ba-L with an IC50 of 11 lM. More-
over, this compound presents a PAF-antagonism with
an 8 lM IC50 on PAF-induced platelet aggregation, that
would enable it to diminish neurotoxic disorders gener-
ated by the important production of PAF from the
infected cells in brain tissues.12,13
In a previous study,14 we replaced the carbamate group
of 1a with other functions (ureate, thiocarbamate. . .)
and evaluated the inﬂuence of this modiﬁcation on both
anti-PAF and anti-HIV-1 activities. The results obtained
showed that compounds with a higher antiviral activity
coupled or not with a PAF-antagonism can be obtained.Figure 1. PMS 601.
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Scheme 1. Reagents and conditions: (a) TMBCl or Ph3CCl, Et3N, CH2Cl2, 0 
NaBH4, MeOH, 0 C; (d) PhOCOCl, pyr, CH2Cl2, 0 C; (e) 1—HN(Et)2, reﬂuIn this work, the carbamate function of 1a was main-
tained and new substituents were introduced on one or
both nitrogens of the piperazine ring in order to modify
either lipophilicity, electronic distribution or steric ef-
fect. These modiﬁcations included (i) the variation of
the number and the position of the methoxy groups on
the aromatic rings, (ii) the transformation of an amide
to a thioamide function, (iii) the suppression of one or
both substituents on the piperazine nitrogens and (iv)
the replacement of one or both trimethoxyphenyl rings
by one or two aryl groups or aromatic heterocycles.
Their inﬂuence on both anti-PAF and anti-HIV-1 activ-
ities was investigated. Moreover, a molecular modelling
analysis has been triggered to calculate 3D electrostatic
potential maps of selected compounds and to study
the conformational space of the sulfur-containing
derivatives.2. Results and discussion
2.1. Chemistry
In Scheme 1, the monosubstitution of 115 using 3,4,5-tri-
methoxybenzoyl chloride (TMBCl) or triphenylmethyl
chloride led to 2 and 9, respectively. Their free nitrogen
was then substituted by either benzyl chloride for 2 lead-
ing to 3 or TMBCl for 9 providing 10. The compound 11
was obtained after deprotection of 10 using HCl in
MeOH and was benzylated into 12. The carbamate
function in 6 and 15 was obtained from the esters 3
and 12, respectively, according to Serradji et al. and
Lamouri et al.12,16 The catalytic hydrogenolysis of 6
and 15 led to 7 and 16, respectively. In Scheme 2, the
free base of 7 was (i) transformed into 8 and 19 using
diphenylmethyl bromide and methyl 2-bromo-2,2-diph-
enylacetate, respectively; (ii) converted, using the Lawes-
son’s reagent,17,18 into its thioamide analogue 17 which
was acylated with TMBCl to give 18; (iii) transformed,
using syringic acid, DCC and HOBT, into 26 which
was alkylated with 1-bromobutane into 27. The reaction
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Scheme 2. Reagents and conditions: (a) (Ph)2CHBr, KI, K2CO3, CH3CN, reﬂux then HCl, EtOH or Ph2C(Br)COOMe, KI, K2CO3, CH3CN, reﬂux
or syringic acid, DCC, HOBT, CH2Cl2, reﬂux; (b) n-BuBr, K2CO3, acetone, reﬂux; (c) 1—NaHCO3, 2—Lawesson’s reagent, THF, 0 C; (d) TMBCl,
Et3N, CH2Cl2; (e) 1—NaHCO3; 2—syringic acid, DCC, HOBT, CH2Cl2, reﬂux or PhPyrCHCl (for 21) or Ph2C(Br)CN (for 22) or ClCH2CN (for
23), KI, K2CO3, CH3CN, reﬂux then HCl, EtOH (for 21); (f) NH2OHÆHCl, K2CO3, EtOH, reﬂux; (g) PhOCOCl, pyr, C6H6, reﬂux.
N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125 8111HOBT provided 20; (ii) 4-[chloro(phenyl)methyl]pyri-
dine or a-bromo-a-phenylbenzeneacetonitrile led to 21
and 22, respectively; (iii) chloroacetonitrile gave 23.
The nitrile function of 23 was converted into the corre-
sponding amidoxime 24, using hydroxylamine, and the
oxadiazolone 25 was obtained after reaction with phenyl
chloroformate followed by an internal cyclization in
reﬂuxing benzene.19 The compounds 29a–e and 30, de-
scribed in Scheme 3, were prepared from 2816 and the
corresponding acid, acyl or alkyl chloride. The com-
pound 1a16 was converted into the corresponding di-thi-
oamide 31 using the Lawesson’s reagent. In Scheme 4,
the monosubstitution of 28 by either diphenylmethyl
bromide or triphenylmethyl chloride led to 32 and 34,
respectively. The acylation of 34 by syringic acid result-
ed in 35 which was alkylated with n-butyl bromide into
36. Compound 38 was obtained after removal of the tri-
tyl group of 36, benzylation of 37 and treatment with the
corresponding HCl salt. The compound 42 was obtained
as previously described for 18.
2.2. Results and discussion
All the compounds were tested for their ability to inhibit
PAF-induced platelet aggregation on the one hand and
to block the viral replication in MDM infected with the
reference macrophage-tropic HIV-1/Ba-L strain on theother hand.12,13 In this new set of experiments, 1a dem-
onstrated identical eﬀects as previously described with
an anti-HIV-1 IC50 and an anti-PAF IC50 equal to 11
and 8 lM, respectively.12 It was then used as the refer-
ence compound to evaluate the impact of the various
modiﬁcations performed in this study. The 1-octanol/
water partition coeﬃcient (logP) of all the molecules
was calculated using ALOGPS program20–22 to evaluate
the inﬂuence of this parameter on both activities
(Table 1).
2.2.1. Inﬂuence of the substituent on the piperazine ring
(Table 1). The deletion of one of both methoxyl groups
at the meta-position (29a) modiﬁes neither the aﬃnity to
the PAF-receptor (PAF-R) nor the antiviral activity of
the compound (42% at 10 lM), while the displacement
of the remaining meta-methoxyl to the ortho-position
(29b) induces a complete loss of both activities. The
modiﬁcation of the electrostatic wells in the ‘cache-oreil-
les’ eﬀect23,24 and/or an increase of steric hindrance at
the ortho-position could explain this diﬀerence between
29a and 29b. The compound 29d, which does not bear
any methoxyl group, does not present a better activity
than 1a, supporting the importance of the electronic
properties of these substituents towards, at least, the
PAF-antagonism. Indeed, 29f, which is the HCl salt of
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Scheme 4. Reagents and conditions: (a) Ph3CCl, Et3N, CH2Cl2, 0 C or (Ph)2 CHBr, KI, K2CO3, CH3CN, reﬂux; (b) syringic acid, DCC, HOBT,
CH2Cl2, reﬂux or TMBCl, Et3N, CH2Cl2 then HCl, EtOH (for 33); (c) CH3(CH2)2CH2Br, K2CO3, acetone, reﬂux; (d) HCl, MeOH, 0 C;
(e) 1—BzlCl, KI, K2CO3, CH3CN, reﬂux; 2—HCl, EtOH; (f) Lawesson’s reagent, THF, 0 C.





















































Scheme 3. Reagents and conditions: (a) ZCl, KI, K2CO3, CH3CN, reﬂux or Et3N, CH2Cl2 or ZCOOH, DCC, HOBT, CH2Cl2, reﬂux then HCl,
EtOH for 30; (b) Lawesson’s reagent, THF, 0 C.
8112 N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125nocarbonyloxymethylpiperazine,16 presents an anti-
PAF activity higher than 100 lM. The absence of anti-
PAF activity of 29c can be explained by the orientation
of the two hydroxyles on the aromatic rings to enable an
intramolecular hydrogen bond with the neighbouring
methoxyl as observed during its geometry optimization.This is associated with a decrease of the electrostatic
negative potentials generated by the methoxyle as shown
in Figure 3 and suggests that this compound cannot
interact properly with the PAF-R as its large
‘cache-oreilles’ system is not available.23,24 Lipophilicity
of 29c (log P = 2.21) seems to be less implicated in the
Table 1. Inﬂuence of the substituent on the piperazine ring






























2.21 >100 35 >100 >2.85
29d C
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2.39 >10 43% (100 lM) >100 >1
29e N C
O
0.26 >10 35% (100 lM) >100 >1






CH2, HCl 3.02 2.5 75% (10 lM) >10 >1
a 1-Octanol/water partition coeﬃcient calculated using ALOGPS2.1 program.20–22
b Inhibition of PAF-induced platelet aggregation using platelet-rich plasma (PRP) of New Zealand rabbits calculated from dose–response curve as
described in Section 4 (n = 5, mean ± 10%).
c Antiviral activity determined with HIV-1/Ba-L-infected monocyte-derived macrophages. All experiments were performed in triplicate in cells
isolated from one blood donor (mean ± 10%).
d Cytotoxicity evaluated by neutral red staining on MDM.
e Antiviral selectivity index (toxicity/antiviral IC50).
f See Ref. 12.
g HCl salt of the previously described compound.14
h Toxic at 100 lM.
N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125 8113variation of this activity as it is close to that of 1a
(logP = 2.88). The antiviral potency of this compound
remains similar to that of 1a. The replacement of the
carbonyls of 1a by methylenes in the compound 30 leads
to an increase of both activities. When both 3,4,5-trime-
thoxybenzoyl groups are replaced simultaneously by
two benzyls as in 29f, the antiviral activity is surprisingly
increased. Indeed, we saw that the deletion of the
methoxyl groups in 29d does not lead to an increase of
the antiviral activity. Nevertheless, this observation
should be associated with the presence of the benzoyls
in 29d whereas 29f bears two benzyls. These compounds
are devoid of anti-PAF activity probably because the
negative electrostatic wells induced by the two benzyl
or benzoyl groups are not suﬃcient enough to enablea proper interaction of the compound with the PAF-
R.25 The introduction of a nitrogen in the aromatic ring
in compound 29e in order to modify the electronic distri-
bution of the substituent does not improve both activi-
ties (Table 2).
2.2.2. Inﬂuence of sulfur towards antiviral and anti-PAF
activities (Table 2). The transformation of one or both
amide functions to thioamide ones leads, in all cases
(compounds 18, 31 and 42), to an increase of the anti-
PAF activity probably through the augmentation of
the lipophilicity of the molecules as shown by thin-layer
chromatography in MeOH/CH2Cl2 (5:95, v/v);
Rf(1a) = 0.33 versus Rf(18) = 0.42 versus Rf(31) = 0.55.
The position of the thioamide function seems to be

























































3.30 0.44 >100 >100 —
a 1-Octanol/water partition coeﬃcient calculated using ALOGPS2.1 program.20–22
b Inhibition of PAF-induced platelet aggregation using platelet-rich plasma (PRP) of New Zealand rabbits calculated from dose–response curve as
described in Section 4 (n = 5, mean ± 10%).
c Antiviral activity determined with HIV-1/Ba-L infected monocytes derived macrophages. All experiments were performed in triplicate in cells
isolated from one blood donor (mean ± 10%).
d Cytotoxicity evaluated by neutral red staining on MDM.
e Antiviral selectivity index (toxicity/antiviral IC50).
f See Ref. 12.
g Toxic at 100 lM.
8114 N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125important for the anti-HIV-1 activity because no such
activity was detected when it is at the N1-position (42),
whereas at the N4-position, the corresponding com-
pound 18 presents an antiviral activity close to that of
the leader, 1a. This diﬀerence of antiviral activity could
be explained by the electronic eﬀect induced by the pres-
ence of the sulfur at the N1-position: it probably dis-Figure 2. 3D electrostatic maps of 1a and 42 (isocontours drawn at 20 kcaturbs the electronic environment of the carbamate
function, known to be involved in the antiviral activity
of the molecule.12 Nevertheless, the presence of two thi-
oamide functions in the compound 31 confers to it an
antiviral activity which is even higher than that of 1a.
Thus, this compound presents a better dual activity than
1a in spite of its toxicity at 100 lM.l/mol).
Figure 3. 3D electrostatic map of 29c (isocontours drawn at 20 kcal/
mol).







N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125 81152.2.3. Molecular modelling. This study was initiated to
assess the inﬂuence of the introduction of the sulfur
atom in the compounds 18, 31 and 42. The 3D electro-
static potential maps of 1a and 42 (isocontoured at
20 kcal/mol, Fig. 2) show that the introduction of a
sulfur atom in the amide linkage in 42 does not clearly
modify the electronic well observed in 1a. This observa-
tion led us to perform a conformational analysis study
of these compounds to determine their energetically
accessible space. Their geometries were fully optimized
using the double basis set 6-31g.26 The geometry optimi-
zation carried out shows that four minima of relative
energy can be found for each molecule: two boat and
two chair conformations (Table 3).
For each conformer, the cisoid and transoid rotamers
can be located.16 These four conformations are not
equal in energy. For all the compounds, the chair con-
formations are the most stable (DE close to 0.0 kcal/
mol) but an additional stable boat conformer appears
for 18 as its relative energy is 0.639 kcal/mol. We can ob-
serve that the carbamate linkage takes place, in each
conformer, to enable intramolecular interactions
(hydrogen bonds). Moreover, the activation energy be-
tween the two chair conformers was calculated and the
results are listed in Table 4. These values demonstrate
that the interconversion between both conformers is eas-
ier for 1a and 18 than for 31 and 42 and thus, the con-
formational ﬂexibility of these compounds is diﬀerent.
This study indicates that each molecule presents a specif-
ic conformational proﬁle. Neither the mode of action ofTable 3. Calculated conformational energies and conformations of compoun
Compound DE (k
1a 0.0 (/ = 26), chair 0.159 (/ = 170), cha
18 0.0 (/ = 14), chair 0.639 (/ = 171), boa
31 0.0 (/ = 14), chair 0.829 (/ = 172), cha
42 0.0 (/ = 30), chair 1.966 (/ = 169), chathe studied piperazine derivatives nor their biological
target is identiﬁed in the antiviral assay. Nevertheless,
we can assume that the population of the conformers
at the active site will diﬀer from one molecule to anoth-
er, probably contributing to the diﬀerence of antiviral
activity observed.
2.2.4. Modiﬁcation of the N1-substituent (Table 5). The
non-substitution of this nitrogen in 7 leads to a total loss
of both activities. This result shows that the presence of
a substituent on both positions, 1 and 4, of the pipera-
zine ring is essential. The replacement of one trime-
thoxybenzoyl group (1a) with a benzyl one as in 6
does not modify the anti-PAF activity. Indeed, we
showed, in a previous work,25 that the decrease of the
electrostatic well due to the replacement of one trime-
thoxybenzoyl group by a benzyl moiety is balanced by
its higher lipophilicity. The introduction of a diphenylm-
ethyl moiety, more hydrophobic and sterically hindered,
in the compounds 8 and 19 leads to an increase of the
anti-PAF potency as expected but this amelioration is
associated with an increased toxicity on macrophages
and then seems baneful for the anti-HIV-1 activity. In-
deed, 19 which presents a sub-micromolar anti-PAF
potency is toxic on macrophages at 10 lM and inactive
at 1 lM. To increase the lipophilic anchorage of the
molecule in the PAF-R and thus, the anti-PAF activity,
we prepared 27 with a butyl moiety on the aromatic
ring. This modiﬁcation conferred an important anti-
PAF potency to the molecule but it is devoid of antiviral
activity. Other factors such as the steric hindrance
should be investigated to try to explain the variations
of antiviral activity.
2.2.5. Modiﬁcation of the N4-substituent (Table 6). Com-
pound 16, as its position analogue 7 (Table 5), is totally
inactive. The introduction of a benzyl group in 15 is
without eﬀect on the anti HIV-1 activity but leads to a
decrease of the anti-PAF one, whereas its isomer 6 (Ta-
ble 5) presents the same range of activities as 1a. This
suggests that both positions of the piperazine ring are
not equivalent. Derivative 33, which exhibits an anti-
PAF activity as good as its analogue 8 (Table 5), could
not be tested for its antiviral property because of the ab-
sence of a dose–eﬀect relationship during the evaluation.
The modiﬁcation of the lipophilicity of the substituentds 1a, 18, 31 and 42
cal/mol), conformation
ir 2.400 (/ = 21), boat 4.959 (/ = 188), boat
t 0.763 (/ = 173), chair 2.595 (/ = 5), boat
ir 2.335 (/ = 19), boat 2.547 (/ = 173), boat
ir 4.429 (/ = 20), boat 4.823 (/ = 172), boat







Compound Z logPa Anti-PAFb IC50 (lM) Anti-HIV-1








2.88 8 11 >1000 > 90
6 CH2, HCl 3.39 6 40 >100 > 2.5
7 –H,HCl 1.38 >100 >100 >100 —
8 , HCl 3.66 0.75 3 P100g P33.3
19
COOMe







3.96 0.001 >100 > 100 —
a 1-Octanol/water partition coeﬃcient calculated using ALOGPS2.1 program.20–22
b Inhibition of PAF-induced platelet aggregation using platelet-rich plasma (PRP) of New Zealand rabbits calculated from dose response curve as
described in Section 4 (n = 5, mean ± 10%).
c Antiviral activity determined with HIV-1/Ba-L infected monocytes derived macrophages. All experiments were performed in triplicate in cells
isolated from one blood donor (mean ± 10%).
d Cytotoxicity evaluated by neutral red staining on MDM.
e Antiviral selectivity index (toxicity/antiviral IC50).
f See Ref. 12.
g Toxic at 100 lM.
hNot determined as toxic at 10 lM and inactive at 1 lM.
8116 N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125and/or the introduction of an heterocyclic moiety able to
generate an electrostatic potential well as in the com-
pounds 20, 21, 22 and 25 modiﬁes the anti-PAF activity
without leading to an increase of the antiviral activity,
suggesting that other factors than these are involved in
this pharmacological activity.
2.2.6. Modiﬁcation of the N1- and N4-substituents (Table
7). The compounds 15 (Table 6) and 29f (Table 1) pres-
ent an anti-HIV-1 activity equivalent to or higher than
that of 1a and are devoid of PAF-antagonism, whereas
27 (Table 5) presents the best anti-PAF activity of the
series without any antiviral potency. To take advantage
of these observations, we synthesized 38 which presents
a benzyl at the N4 position of the piperazine and a butyl
moiety on the aromatic ring. The results show that the
antiviral activity is not maintained with this structure,
which inhibits only 40% of the viral replication at
5 lM and is toxic at 20 lM. The lack of anti-PAF activ-ity of this molecule, and of compounds 15 and 29f,
seems to be linked to the presence of a benzyl group
at the N4-position of piperazine. We can note that in this
case, the high lipophilicity of the molecule is not suﬃ-
cient to confer to it a notable anti-PAF activity.3. Conclusion
In summary, we have ameliorated the anti-PAF potency
of our reference 1a by modifying the substituents of the
piperazine nitrogens. We can note that here again, both
activities do not seem to be correlated as pure antiviral
compounds with micromolar eﬃcacy (15 and 29f) were
obtained. We noticed that the parameters controlling
the anti-PAF activity (i.e., hydrophobicity and
‘cache-oreilles’ eﬀect) previously described do not seem
to be clearly implicated in the variation of the antiviral
activity in this set of compounds.








Compound Y logPa Anti-PAFb IC50 (lM) Anti-HIV-1








2.88 8 11 >1000 >90
15 CH2, HCl 3.39 >100 13 >100 >7.69







2.93 44% (10 lM) 66% (100 lM) >100 >1
21
N
4.06 1.25 27% (10 lM) P100g P10
22
CN





CH2 1.58 >10 13% (100 lM) >100 <1
33 , HCl 3.66 0.6 NDh NDh —
a 1-Octanol/water partition coeﬃcient calculated using ALOGPS2.1 program.20–22
b Inhibition of PAF-induced platelet aggregation using platelet-rich plasma (PRP) of New Zealand rabbits calculated from dose–response curve as
described in Section 4 (n = 5, mean ± 10%).
c Antiviral activity determined with HIV-1/Ba-L infected monocytes derived macrophages. All experiments were performed in triplicate in cells
isolated from one blood donor (mean ± 10%).
d Cytotoxicity evaluated by neutral red staining on MDM.
e Antiviral selectivity index (toxicity/antiviral IC50).
f See Ref. 12.
g Toxic at 100 lM.
hNot determined.
N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125 8117Otherwise, compound 1a does not inhibit either the
main targets of the highly active antiretroviral therapy
(i.e., the reverse transcriptase, the viral protease and
the entry of the virus in the cell) or the viral inte-
grase.12,13 Additional studies are under consideration
to clarify the mode of action of this compound. Indeed,
the isolation and characterization of its biological target
would enable us to ameliorate our structure-activity
relationship.4. Experimental
4.1. General
All materials were obtained from commercial suppliers
(e.g., Acros, Aldrich, Fluka, Paris, France) and used
without further puriﬁcation. Thin-layer chromatogra-
phy was performed on TLC plastic sheets of silica gel
60F254 (layer thickness 0.2 mm) from Merck. Column


























3.95 >100 40% (5 lM) P20g < 5
a 1-Octanol/water partition coeﬃcient calculated using ALOGPS2.1 program.20–22
b Inhibition of PAF-induced platelet aggregation using platelet-rich plasma (PRP) of New Zealand rabbits calculated from dose–response curve as
described in Section 4 (n = 5, mean ± 10%).
c Antiviral activity determined with HIV-1/Ba-L infected monocytes derived macrophages. All experiments were performed in triplicate in cells
isolated from one blood donor (mean ± 10%).
d Cytotoxicity evaluated by neutral red staining on MDM.
e Antiviral selectivity index (toxicity/antiviral IC50).
f See Ref. 12.
g Toxic at 20 lM.
8118 N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125chromatography puriﬁcation was carried out on silica
gel 60 (70–230 mesh ASTM, Merck). All melting points
were determined on a digital melting point apparatus
(Electrothermal) and are uncorrected. The structures
of all compounds were conﬁrmed by IR and 1H and
13C NMR spectra. IR spectra were obtained in paraﬃn
oil with a ATI Mattson Genesis Series FTIR spectrom-
eter, and 1H NMR and 13C NMR spectra were recorded
in CDCl3 or in DMSO-d6 on a BRUCKER AC 200
spectrometer using hexamethyldisiloxane (HMDS) as
an internal standard. Chemical shifts are given in ppm
and peak multiplicities are designated as follows: br s,
broad singlet; s, singlet; d, doublet; dd, doublet of dou-
blet; t, triplet; m, multiplet; qt, quintuplet; sex, sextuplet.
Elemental analyses were obtained from the ‘Service
re´gional de microanalyse’ (Universite´ Paris 6—Pierre




perazine (2). To a cooled (ice bath) solution of 115
(20 g, 86 mmol) and Et3N (42 mL, 301 mmol) in CH2Cl2
(400 mL) was added dropwise a solution of 3,4,5-trime-
thoxybenzoyl chloride (19.83 g, 86 mmol) in CH2Cl2
(200 mL). After the disappearance of the initial amine,
as shown by TLC, the solution was washed with saturat-
ed NaHCO3 solution and water until neutral pH. After
drying (MgSO4), ﬁltration and evaporation, the residue
was chromatographed on a silica gel column using
MeOH/CH2Cl2 (1:99, v/v) as eluent to give the title com-
pound (16.15 g, 53%) as a wax; Rf: 0.24 (MeOH/
CH2Cl2, 3:97, v/v); IR (m cm
1) 3333 (NH), 1736
(C@O ester), 1630 (C@O amide), 1584 (ArC@C); 1HNMR d 6.59 (s, 2H, ArH), 4.16 (q, 2H, J = 7.05 Hz,
CH2O), 3.81 (s, 9H, CH3O), 3.68–3.10 (m, 5H, pipera-
zine), 3.04 (m, 1H, piperazine), 2.75 (m, 1H, piperazine),
2.28 (s, 1H, NH), 1.20 (t, 3H, J = 7.07 Hz, CH3).
4.2.2. 1-Benzyl-2-ethoxycarbonyl-4-(3,4,5-trimethoxyben-
zoyl)piperazine (3).Amixture of 2 (18 g, 51 mmol), benzyl
chloride (7.74 g, 61 mmol), K2CO3 (10 g, 72.46 mmol)
and KI (cat.) in CH3CN (200 mL) was reﬂuxed for 3 h.
After ﬁltration of the salts and evaporation of the ﬁltrate,
the residue was taken in CH2Cl2, washed several times
with water, dried (MgSO4), ﬁltered and evaporated. A
puriﬁcation on a silica gel column using CH2Cl2 as eluent
yielded 3 (21.84 g, 97%) as a wax; Rf: 0.65 (MeOH/
CH2Cl2, 3:97, v/v); IR (m cm
1) 1727 (C@O ester), 1630
(C@O amide), 1584 (ArC@C); 1H NMR d 7.22 (m, 5H,
ArH), 6.58 (s, H, ArH), 6.56 (s, H, ArH), 4.11 (m, 3H,
CH2O, piperazine), 3.83 (m, 1H, CH–Ph), 3.78 (s, 9H,
CH3O), 3.58 (m, 3H, CH–Ph, piperazine), 3.30 (m, 2H,
piperazine), 3.09 (m, 1H, piperazine), 2.37 (m, 1H, piper-
azine), 1.19 (m, 3H, CH3).
4.2.3. 1-Benzyl-2-hydroxymethyl-4-(3,4,5-trimethoxyben-
zoyl)piperazine (4). The same procedure as described in
Tavet et al.28 was used to prepare the compound 4.
Reduction of the ester 3 (21.8 g, 27.4 mmol) yielded,
after a puriﬁcation on a silica gel column using
MeOH/CH2Cl2 (1:99, v/v) as eluent, 4 (4.31 g, 28%) as
a wax; Rf: 0.28 (MeOH/CH2Cl2, 3:97, v/v); IR (m
cm1) 3400 (OH), 1618 (C@O amide), 1584 (ArC@C);
1H NMR d 7.26 (m, 5H, ArH), 6.56 (s, 2H, ArH),
4.04 (d, 2H, J = 13.19 Hz, CH–Ph), 3.82 (m, 3H, piper-
azine), 3.78 (s, 9H, CH3O), 3.73–3.36 (m, 5H, CH2OH,
piperazine), 3.50 (d, 2H, J = 13.34 Hz, CH–Ph), 2.77
(m, 2H, piperazine), 2.35 (m, 1H, piperazine).
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trimethoxybenzoyl)piperazine (5). Following the proce-
dure described in Serradji et al.12 but replacing Et3N
by pyridine, the compound 5 (4 g, 77%) was prepared
from the alcohol 4 (4.31 g, 10 mmol) and phenyl chloro-
formate (3 g, 18 mmol) and obtained as a wax; Rf: 0.66
(MeOH/CH2Cl2, 3:97, v/v); IR (m cm
1) 1761 (C@O car-
bonate), 1631 (C@O amide), 1584 (ArC@C); 1H NMR
(60 MHz) d 7.33 (m, 10H, ArH), 6.66 (s, 2H, ArH),
4.43 (m, 3H, CH2O, CH–Ph), 4.10 (m, 1H, piperazine),
3.81 (s, 9H, CH3O), 3.70–3.26 (m, 4H, CH–Ph, pipera-
zine), 3.16–1.90 (m, 3H, piperazine).
4.2.5. 1-Benzyl-2-N,N-diethylaminocarbonyloxymethyl-4-
(3,4,5-trimethoxybenzoyl)piperazine, hydrochloride (6).
The procedure described in Lamouri et al.16 led to 3.3 g
(88%) of the title compound after a chloridratation using
bubbled HCl in EtOH and a crystallization in acetone/
ether: Rf: 0.20 (MeOH/CH2Cl2, 5:95, v/v); mp 134 C;
IR (m cm1) 3451 (NH+), 1720 (C@O carbamate), 1657
(C@O amide), 1584 (ArC@C); 1H NMR d 13.38 (br s,
1H, NH+), 7.58 (m, 2H, ArH), 7.39 (s, 3H, ArH), 6.55
(s, 2H, ArH), 5.15–3.85 (m, 7H, CH2O, CH2–Ph, pipera-
zine), 3.78 (s, 9H, CH3O), 3.55–2.10 (m, 8H,
N(CH2CH3)2, piperazine), 1.05 (m, 6H, CH3);
13C
NMR d 169.96 (C@O amide), 154.42 (C@O carbamate),
153.27, 139.62, 131.34, 130.20, 129.36, 128.73, 127.39,
104.27 (ArC@C), 61.09 (CH2O), 60.71, 56.11 (CH3O),
57.64 (CH piperazine), 42.07, 41.28 (N(CH2CH3)2),
13.85, 13.13 (CH3). Anal. (C27H38N3ClO6Æ0.75H2O) C,
H, N.
4.2.6. 3-N,N-Diethylaminocarbonyloxymethyl-1-(3,4,5-
trimethoxybenzoyl)piperazine, hydrochloride (7). The cat-
alytic hydrogenation of 6 (2.3 g, mmol), as described in
Serradji et al.,12 led to 7 (460 mg, 24%) as crystals; Rf:
0.44 (MeOH/CH2Cl2, 10:90, v/v); mp 199.3 C; IR (m
cm1) 3404 (NH+), 1703 (C@O carbamate), 1644
(C@O amide), 1585 (ArC@C); 1H NMR d 10.21 (br s,
2H, NH2
+), 6.55 (s, 2H, ArH), 5.20–4.00 (m, 4H,
CH2O, piperazine), 3.80 (s, 9H, CH3O), 3.49 (m, 3H,
piperazine), 3.16 (m, 4H, N(CH2CH3)2), 2.55 (m, 2H,
piperazine), 1.02 (m, 6H, CH3);
13C NMR d 170.41
(C@O amide), 154.66 (C@O carbamate), 153.45,
139.73, 129.02, 104.24 (ArC@C), 61.56 (CH2O), 60.83,
56.28 (CH3O), 54.41, 43.32 (piperazine), 42.18, 41.47
(N(CH2CH3)2), 13.96, 13.25 (CH3). Anal. (C20H32
N3ClO6) C, H, N.
4.2.7. 2-N,N-Diethylaminocarbonyloxymethyl-1-diphe-
nylmethyl-4-(3,4,5-trimethoxybenzoyl)piperazine, hydro-
chloride (8). A mixture of 7 (free base, 300 mg,
0.67 mmole), diphenylmethyl bromide (320 mg,
1.34 mmol), K2CO3 (560 mg, 4 mmol) and KI (60 mg,
0.33 mmole) in CH3CN (9.5 mL) was reﬂuxed for 60 h.
The salts were ﬁltered, washed with CH3CN and the ﬁl-
trate concentrated in vacuum. The residue was taken in
CH2Cl2, washed with a saturated NaHCO3 solution and
water, dried (MgSO4), ﬁltered and evaporated to provide
awaxwhichwas dissolved in EtOHand treated withHCl.
A recrystallization from EtOH/Et2O gave 8 (90 mg, 22%)
as crystals; Rf: 0.57 (MeOH/CH2Cl2, 5:95, v/v); mp
189.5 C; IR (m cm1) 3349 (NH+), 1694 (C@O carba-mate), 1623 (C@O amide), 1580 (ArC@C); 1H NMR d
13.48 (br s, 1H, NH+), 8.00 (d, 2H, J = 6.28 Hz, ArH),
7.88 (d, 2H, J = 5.90 Hz, ArH), 7.30 (m, 6H, ArH), 6.55
(s, 2H, ArH), 5.06 (s, 1H, CH-Ph), 4.61–3.86 (m, 5H,
CH2O, piperazine), 3.76 (s, 9H, CH3O), 3.21–2.67 (m,
8H, CH2CH3, piperazine), 1.02–0.67 (m, 6H, CH3). Anal.
(C33H42N3ClO6) C, H, N.
4.2.8. 3-Ethoxycarbonyl-1-triphenylmethylpiperazine (9).
Compound 9 was prepared as described for 34 but from
1;15 Rf: 0.21 (Et2O); IR (m cm
1) 3349 (NH), 3059
(ArCH), 1723 (C@O ester), 1595 (ArC@C); 1H NMR
d 7.39 (m, 6H, ArH), 7.11 (m, 9H, ArH), 4.05 (m, 2H,
CH2O), 3.85–2.00 (m, 7H, piperazine), 1.86 (s, 1H,
NH), 1.17 (m, 3H, CH3);
13C NMR d 129.24, 127.42,
126.00 (ArC@C), 76.99 (CPh3), 60.77 (CH2O), 48.61
(piperazine), 14.08 (CH3).
4.2.9. 2-Ethoxycarbonyl-1-(3,4,5-trimethoxybenzoyl)-4-
triphenylmethylpiperazine (10). Compound 10 was pre-
pared from 9 as described for 2 but at room temperature;
Rf: 0.38 (Et2O); mp 208.7 C; IR (m cm1) 1738 (C@O es-
ter), 1634 (C@O amide), 1586 (ArC@C); 1H NMR d 7.34
(m, 6H, ArH), 7.17 (m, 9H, ArH), 6.53 (s, 2H, ArH), 4.52
(m, 1H, CHOCO), 4.25 (m, 1H, CHOCO), 3.88–3.62 (m,
13H, CH3O, piperazine), 3.46 (m, 1H, piperazine), 3.00
(m, 2H, piperazine), 1.35 (m, 3H, CH3);
13C NMR d
171.11 (C@O), 170.93 (C@O), 153.27, 153.14, 139.00,
130.71, 129.20, 127.54, 126.35, 104.11 (ArC@C), 76.88
(CPh3), 61.47 (CH2O), 60.77, 56.14 (CH3O), 52.80,
48.75, 48.36, 46.13 (piperazine), 14.16 (CH3).
4.2.10. 2-Ethoxycarbonyl-1-(3,4,5-trimethoxybenzoyl)pi-
perazine (11). Compound 11 was prepared as described
for 40 but from 10 (10.8 g, 75%); Rf: 0.20 (MeOH/
CH2Cl2, 3:97, v/v); IR (m cm
1) 3559 (NH), 1738
(C@O ester), 1637 (C@O amide), 1584 (ArC@C); 1H
NMR d 6.58 (s, 2H, ArH), 4.41 (q, 2H, J = 7.00 Hz,
CH2O), 3.79 (s, 9H, CH3O), 3.65–2.55 (m, 7H, pipera-
zine), 2.27 (s, 1H, NH), 1.18 (t, 3H, J = 7.09 Hz, CH3).
4.2.11. 4-Benzyl-2-ethoxycarbonyl-1-(3,4,5-trimethoxy-
benzoyl)piperazine (12). This compound (9.5 g, 83%)
was prepared as described for the compound 3; Rf:
0.61 (MeOH/CH2Cl2, 3:97, v/v); IR (m cm
1) 1742
(C@O ester), 1641 (C@O amide), 1584 (ArC@C); 1H
NMR d 7.21 (m, 5H, ArH), 6.61 (s, 2H, ArH), 4.70–
3.00 (m, 11H, piperazine, CH2–Ph, CH2O), 3.78 (s,
9H, CH3O), 1.18 (m, 3H, CH3).
4.2.12. 4-Benzyl-2-hydroxymethyl-1-(3,4,5-trimethoxy-
benzoyl)piperazine (13). This compound (1.44 g, 17%)
was prepared following the same procedure as de-
scribed in Tavet et al.28 Rf: 0.24 (MeOH/CH2Cl2,
3:97, v/v); IR (m cm1) 3378 (OH), 1628 (C@O amide),
1584 (ArC@C); 1H NMR d 7.23 (m, 5H, ArH), 6.57 (s,
2H, ArH), 4.69–3.98 (m, 4H, piperazine, OH), 3.77 (s,
9H, CH3O), 3.67 (br s, 2H, CH2OH), 3.43 (s, 2H,
CH2–Ph), 2.86 (m, 2H, piperazine), 2.17 (m, 2H, piper-
azine); 13C NMR d 171.11 (C@O), 153.32, 138.90,
136.92, 131.06, 128.74, 128.37, 127.39, 104.11
(ArC@C), 62.66 (CH2–Ph), 60.72, 56.09 (CH3O),
54.52 (CH2OH), 52.72 (CH2 piperazine).
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trimethoxybenzoyl)piperazine (14). This compound
(1.8 g, 99%) was prepared following the same procedure
as described in Serradji et al.12 Rf: 0.71 (MeOH/CH2Cl2,
3:97, v/v); IR (m cm1) 1757 (C@O carbonate), 1650
(C@O amide), 1584 (ArC@C); 1H NMR d 7.49–7.00
(m, 10H, ArH), 6.59 (s, 2H, ArH), 5.26 (m, 2H,
CH2O), 4.80–3.80 (m, 4H, CH-Ph, piperazine), 3.79 (s,




(15). This compound (1.41 g, 93%) was prepared as de-
scribed for the compound 6; Rf: 0.20 (MeOH/CH2Cl2,
5:95, v/v); mp 180.6 C; IR (m cm1) 3451 (NH+), 1720
(C@O carbamate), 1657 (C@O amide), 1584 (ArC@C);
1H NMR d 12.53 (br s, 1H, NH+), 7.61 (s, 2H, ArH),
7.36 (s, 3H, ArH), 6.62 (s, 2H, ArH), 5.06 (br s, 2H,
piperazine), 4.39 (br s, 2H, piperazine), 4.13 (br s,
2H, CH2O), 3.77 (s, 9H, CH3O), 3.53–2.69 (m, 9H,
CH2-Ph, N(CH2CH3)2, piperazine), 1.1 (m, 6H, CH3).
Anal. (C27H38N3ClO6Æ2H2O) C, H, N.
4.2.15. 2-N,N-Diethylaminocarbonyloxymethyl-1-(3,4,5-
trimethoxybenzoyl)piperazine, hydrochloride (16). This
compound (1.2 g, 85%) was prepared as described for
7; Rf: 0.22 (MeOH/CH2Cl2, 5:95, v/v); mp 194.9 C;
IR (m cm1) 3423 (NH2
+), 1690 (C@O carbamate),
1640 (C@O amide), 1585 (ArC@C); 1H NMR d 9.75
(br s, 2H, NH2
+), 6.58 (s, 2H, ArH), 5.35–3.90 (m,
5H, CH2O, piperazine), 3.80 (s, 9H, CH3O), 3.70–2.70
(m, 8H, N(CH2CH3)2, piperazine), 1.00 (t, J = 6.66 Hz,
6H, CH3);
13C NMR d 170.46 (C@O amide), 155.35
(C@O carbamate), 153.40, 139.75, 129.27, 104.40
(ArC@C), 61.43 (CH2O), 60.83, 56.27 (CH3O), 43.42,
42.78, 41.92, 41.32 (NCH2CH3 carbamate, piperazine),
13.99, 13.34 (NCH2CH3). Anal. (C20H32N3ClO6Æ0.5-
H2O) C, H, N.
4.2.16. 3-N,N-Diethylaminocarbonyloxymethyl-1-(3,4,5-
trimethoxythiobenzoyl)piperazine (17). The same proce-
dure as for the preparation of the compound 41 was fol-




perazine (18). The same procedure as described for 2
but at room temperature was followed to lead to 18
(150 mg, 41%); Rf: 0.42 (MeOH/CH2Cl2, 5:95, v/v);
mp 100.9 C; IR (m cm1) 1691 (C@O carbamate),
1631 (C@O amide), 1584 (ArC@C); 1H NMR d 6.58
(s, 2H, ArH), 6.45 (m, 2H, ArH), 5.30–4.70 (m, 2H,
piperazine), 4.50–4.00 (m, 3H, CH2O, piperazine), 3.80
and 3.77 (2s, 18H, CH3O), 3.60–2.60 (m, 8H,
N(CH2CH3)2, piperazine), 1.03 (m, 6H, CH3);
13C
NMR d 202.23 (C@S), 170.54 (C@O amide), 155.00
(C@O carbamate), 153.24, 139.55, 138.43, 137.53,
129.83, 129.62, 104.31 (ArC@C), 61.15 (CH2O), 60.70,
60.65, 56.12 (CH3O), 51.65, 49.30, 48.77 (piperazine),
41.75, 41.00 (NCH2CH3), 13.93, 13.26 (NCH2CH3).
Anal. (C30H41N3O9S) C, H, N.4.2.18. 3-N,N-Diethylaminocarbonyloxymethyl-1-(3,4,5-
trimethoxybenzoyl)-4-(methoxycarbonyldiphenylmeth-
yl)piperazine (19). Compound 19 was prepared follow-
ing the same process as for the compound 3, but from
methyl 2-bromo-2,2-diphenylacetate and 7. A recrystal-
lization from CH2Cl2/hexane yielded 400 mg (14%) of
the title compound; Rf: 0.1 (MeOH/CH2Cl2, 2:98, v/v);
mp 149.9 C; IR (m cm1) 1729 (C@O ester), 1694
(C@O carbamate), 1633 (C@O amide), 1584 (ArC@C);
1H NMR d 7.38 (m, 4H, ArH), 7.23 (m, 6H, ArH),
6.51 (s, 2H, ArH), 3.96 (m, 3H, CH2OC@O, piperazine),
3.76 and 3.74 (2s, 9H, CH3O), 3.72 (s, 3H, CH3OC@O),
3.65–2.30 (m, 10H, N(CH2CH3)2, piperazine), 0.97 (m,
6H, CH3);
13C NMR d 172.89 (C@O ester), 170.75
(C@O amide), 153.07, 140.20, 139.93, 131.05, 128.86,
128.59, 128.05, 127.95, 127.53, 127.39, 104.23 (ArC@C),
78.64 (CH2 ester), 61.47 (CH2O), 60.68, 56.12
(CH3O), 53.25 (CH3 ester), 52.27 (CH piperazine),
42.90, 41.43 (NCH2CH3), 13.50 (NCH2CH3). Anal.
(C35H43N3O8Æ0.75H2O) C, H, N.
4.2.19. 2-N,N-Diethylaminocarbonyloxymethyl-4-(4-hy-
droxy-3,5-dimethoxybenzoyl)-1-(3,4,5-trimethoxybenzo-
yl)piperazine (20). A mixture of 16 (free base, 3 g,
7.33 mmol), syringic acid (1.5 g, 8.06 mmol), N,N 0-dic-
yclohexylcarbodiimide (1.55 g, 8.06 mmol) and 1-
hydroxybenzotriazole (1.2 g, 8.06 mmol) in CH2Cl2was
reﬂuxed overnight. The mixture was then ﬁltered and
the ﬁltrate washed with saturated NaHCO3 solution
and water, dried (MgSO4), ﬁltered and the solvent elim-
inated. The residue was chromatographed through a sil-
ica gel column using MeOH/CH2Cl2 (1:99, v/v) as eluent
and recrystallized from MeOH/Et2O. The titled com-
pound was obtained (3.67 g, 84.5%) as white crystals;
Rf: 0.21 (MeOH/CH2Cl2, 5:95, v/v); mp 129.3 C; IR
(m cm1) 3373 (OH), 1686 (C@O carbamate), 1617
(C@O amide), 1586 (ArC@C); 1H NMR d 6.61 (s, 2H,
ArH), 6.57 (s, 2H, ArH), 5.69 (s, 1H, OH), 5.30–3.90
(m, 5H, CH2OC@O, piperazine), 3.80 (s, 15H, CH3O),
3.60–2.40 (m, 8H, N(CH2CH3)2, piperazine), 1.01 (m,
6H, CH3);
13C NMR d 171.06, 170.62 (C@O amide),
155.05 (C@O carbamate), 153.26, 146.91, 139.46,
136.58, 130.21, 125.35, 104.42, 104.25 (ArC@C), 60.89
(CH2O), 60.76, 56.38, 56.15 (CH3O), 41.72, 41.01
(NCH2CH3), 13.80, 13.29 (NCH2CH3). Anal.
(C29H39N3O10Æ1.5H2O) C, H, N.
4.2.20. 2-N,N-Diethylaminocarbonyloxymethyl-4-(phen-
yl(pyridin-4-yl)methyl)-1-(3,4,5-trimethoxybenzoyl)piper-
azine (21). The same procedure as for the preparation of
compound 3 was used to prepare the compound 21
(890 mg, 53%) as white crystals from 4-[chloro(phen-
yl)methyl]pyridine and 16: Rf: 0.44 (MeOH/CH2Cl2,
5:95, v/v); mp 79.1 C; IR (m cm1) 1692 (C@O carba-
mate), 1662 (C@O amide), 1583 and 1505 (ArC@C); 1H
NMR d 8.40 (s, 1H, ArH), 7.54 (s, 2H, ArH), 7.39 (m,
2H, ArH), 7.12 (m, 4H, ArH), 6.54 (s, 2H, ArH), 5.20-
3.85 (m, 4H, CH2O, Pyr–CH–Ph, piperazine), 3.78 and
3.75 (2s, 9H, CH3O), 3.75–2.50 (m, 8H, N(CH2CH3)2,
piperazine), 2.25–1.90 (m, 2H, piperazine), 1.06 (m, 3H,
CH3), 0.91 (m, 3H, CH3);
13C NMR d 170.27 (C@O
amide), 161.69, 161.52, 153.16, 149.10, 140.43, 140.28,
139.10, 136.85, 131.02, 128.73, 128.02, 127.87, 127.54,
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77.50 (CH-Pyr), 62.38 (CH2O), 60.78, 56.14 (CH3O),
51.85, 41.78, 41.21 (CH2), 16.25, 13.97, 13.48 (CH3).
Anal. (C32H39N4O6Æ0.5H2O) C, H, N.
4.2.21. 2-N,N-Diethylaminocarbonyloxymethyl-4-(cyan-
odiphenylmethyl)-1-(3,4,5-trimethoxybenzoyl)piperazine
(22). The same procedure as for the preparation of the
compound 3, but starting from a-bromo-a-phenyl-ben-
zeneacetonitrile and 16 (free base), was used to prepare
the compound 22 (100 mg, 4.5%) as white crystals; Rf:
0.37 (MeOH/CH2Cl2, 3:97, v/v); mp 176.4 C; IR (m
cm1) 1701 (C@O carbamate), 1627 (C@O amide), 1584
(ArC@C); 1H NMR d 7.57 (m, 4H, ArH), 7.20 (m, 6H,
ArH), 6.54 (s, 2H, ArH), 5.18–3.98 (m, 3H, CH2O, piper-
azine), 3.77 and 3.73 (2s, 9H, CH3O), 3.70–1.93 (m, 10H,
N(CH2CH3)2, piperazine), 1.33–0.78 (m, 6H, CH3);
13C
NMR d 170.15 (C@O amide), 155.36 (C@O carbamate),
153.09, 139.07, 138.52, 138.39, 130.52, 129.49, 129.00,
128.46, 125.75 (ArC@C), 115.89 (CN), 104.11 (ArC@C),
75.39 (C–CN), 61.91 (CH2O), 60.61, 56.03 (CH3O), 49.10,
48.82, 41.69, 41.03 (CH2), 13.80, 13.32 (NCH2CH3).
Anal. (C34H40N4O6) C, H, N.
4.2.22. 4-Cyanomethyl-2-N,N-diethylaminocarbonyl-
oxymethyl-1-(3,4,5-trimethoxybenzoyl)piperazine (23). A
mixture of 16 (free base, 3 g, 7.4 mmol), chloroacetonit-
rile (950 mg, 12.58 mmol), K2CO3 (6.2 g, 44.4 mmol)
and KI (cat.) in CH3CN (50 mL) was reﬂuxed overnight.
After ﬁltration of the salts, the solvent was removed in
vacuum. The residue was then taken in CH2Cl2, washed
with saturated NaHCO3 solution (2· 50 mL) and water.
The organic layer was dried over MgSO4, ﬁltered and
the solvent was removed under reduced pressure. The
product was then recrystallized from MeOH/Et2O to
give 23 (1.8 g, 55%) as white crystals; Rf: 0.44 (MeOH/
CH2Cl2, 5:95, v/v); mp 160.8 C; IR (m cm1) 2228
(CN), 1690 (C@O carbamate), 1624 (C@O amide),
1583 (ArC@C); 1H NMR d 6.56 (s, 2H, ArH), 5.40–
4.20 (m, 2H, CHOC@O, piperazine), 4.18 (dd, 1H,
J = 6.70 and 10.44 Hz, CHOC@O), 3.80 and 3.78 (2s,
9H, CH3O), 3.70–3.35 (m, 2H, piperazine), 3.48 (s,
2H, CH2CN), 3.19 (m, 4H, N(CH2CH3)2), 2.90–2.45
(m, 3H, piperazine), 2.34 (m, 1H, piperazine), 1.03 (t,
6H, J = 7.05 Hz, CH3);
13C NMR d 170.36 (C@O
amide), 155.29 (C@O carbamate), 153.18, 139.21,
130.51, 104.22 (ArC@C), 113.86 (CN), 62.06 (CH2O),
60.71, 56.11 (CH3O), 51.83, 51.51, 45.95, 41.73, 41.14
(NCH2CH3,piperazine), 13.95, 13.36 (NCH2CH3).
4.2.23. 2-N,N-Diethylaminocarbonyloxymethyl-4-N-
hydroxyamidinomethyl-1-(3,4,5-trimethoxybenzoyl)piper-
azine (24). A mixture of 23 (1.75 g, 3.90 mmol), hydrox-
ylamine, hydrochloride (1.35 g, 19.5 mmol) and K2CO3
(2.7 g, 19.5 mmol) in absolute EtOH (50 mL) was re-
ﬂuxed for 7 h. After the ﬁltration of the salts and the
evaporation of the solvent, the residue was puriﬁed by
silica gel column chromatography using MeOH/CH2Cl2
(3:97, v/v) as eluent to yield 24 (1.4 g, 74.6%) as a wax;
Rf: 0.14 (MeOH/CH2Cl2, 5:95, v/v); IR (m cm
1) 3474
(OH), 3360 and 3182 (NH2), 1699 (C@O carbamate),
1667 (C@N), 1627 (C@O amide), 1583 (ArC@C); 1H
NMR d 6.54 (s, 2H, ArH), 4.93 (s, 2H, NH2), 4.70–3.93 (m, 4H, CH2OC@O, N–OH, piperazine), 3.79 (s,
9H, CH3O), 3.64–2.40 (m, 10H, N(CH2CH3)2, CH2–
C@N, piperazine), 2.12 (m, 2H, piperazine), 1.05 (t,
6H, J = 6.35 Hz, CH3);
13C NMR d 170.45 (C@O
amide), 155.52 (C@O carbamate), 153.16 (C@N–OH),
151.05, 139.20, 130.67, 104.28 (ArC@C), 61.85
(CH2O), 60.74 (CH3O), 57.40 (CH2-amidoxime), 56.12




trimethoxybenzoyl)piperazine (25). Phenyl chlorofor-
mate (440 lL, 3.49 mmol) was added dropwise to a solu-
tion of 24 (1.4 g, 2.91 mmol) and pyridine (300 lL,
3.49 mmol) in dry benzene. The solution was reﬂuxed
for 3 h and was then concentrated in vacuum. The resi-
due was taken in CH2Cl2, washed with water, dried
(MgSO4), ﬁltered and the solvent removed. A puriﬁca-
tion through a silica gel column using MeOH/CH2Cl2
(1:99, v/v) as eluent and a recrystallization from
MeOH/Et2O/hexane yielded 25 (500 mg, 34%) as white
crystals; Rf: 0.27 (MeOH/CH2Cl2, 5:95, v/v); mp
173.4 C; IR (m cm1) 1779 (C@O oxadiazolone), 1673
(C@O carbamate), 1631 (C@O amide), 1584 (ArC@C);
1H NMR d 10.60 (br s, 1H, NH), 6.56 (s, 2H, ArH),
4.91 (br s, 2H, CH2-cycle), 3.95 (m, 2H, CH2OC@O),
3.79 (s, 9H, CH3O), 3.66–3.00 (m, 7H, N(CH2CH3)2,
piperazine), 2.76 (m, 2H, piperazine), 2.37 (m, 2H,
piperazine), 1.04 (t, 6H, J = 6.51 Hz, CH3);
13C NMR
d 170.59 (C@O amide), 159.62 (C@O cycle), 157.28
(C@N), 155.85 (C@O carbamate), 153.36, 139.37,
130.43, 104.20 (ArC@C), 61.19 (CH2O), 60.84, 56.24
(CH3O), 52.47, 51.63, 42.10, 41.36 (NCH2CH3), 13.98,
13.36 (NCH2CH3). Anal. (C23H33N5O8) C, H, N.
4.2.25. 2-N,N-Diethylaminocarbonyloxymethyl-1-(4-hy-
droxy-3,5-dimethoxybenzoyl)-4-(3, 4,5-trimethoxybenzo-
yl)piperazine (26). A mixture of 7 (free base, 0.5 g,
1.22 mmol), syringic acid (242 mg, 1.22 mmol), DCC
(252 mg, 1.22 mmol) and HOBT (198 mg, 4.68 mmol)
was reﬂuxed in CH2Cl2 (15 mL) for 24 h. The mixture
was then ﬁltered, washed twice with saturated NaHCO3
solution and water, dried, ﬁltered and evaporated under
reduced pressure. A chromatography on a silica gel col-
umn using MeOH/CH2Cl2 (2:98, v/v) and a recrystalliza-
tion from MeOH/Et2O gave 26 (0.5 g, 70%) as white
crystals; Rf: 0.37 (MeOH/CH2Cl2, 5:95, v/v); mp
152.6 C; IR (m cm1) 3175 (OH), 1693 (C@Ocarbamate),
1624 (C@O amide), 1574 (ArC@C); 1H NMR d 6.61 (s,
2H, ArH), 6.65 (s, 2H, ArH), 5.94 (br s, 1H, OH), 5.70–
4.17 (m, 3H, piperazine), 4.03 (m, 2H, CH2O), 3.78 (s,
15H, CH3O), 3.77–3.03 (m, 8H, N(CH2CH3)2, pipera-
zine), 0.97 (m, 6H, CH3);
3C NMR d 170.81, 170.75
(C@O amide), 155.03 (C@O carbamate), 153.26, 146.84,
139.34, 136.65, 130.01, 125.47, 104.50, 104.23 (ArC@C),
60.86 (CH2O), 60.76, 56.28, 56.15 (CH3O), 41.73, 41.02
(NCH2CH3), 13.81, 13.27 (NCH2CH3).
4.2.26. 2-N,N-Diethylaminocarbonyloxymethyl-1-(4-but-
oxy-3,5-dimethoxybenzoyl)-4-(3,4,5-trimethoxybenzoyl)-
piperazine (27). A mixture of 26 (0.3 g, 0.51 mmol), 1-
bromobutane (100 lL, 1.02 mmol) and K2CO3
8122 N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125(140 mg, 1.02 mmol) was reﬂuxed in acetone (10 mL) for
48 h. The solution was then evaporated and the residue
taken in CH2Cl2, washed with water, dried, ﬁltered and
the solvent eliminated under reduced pressure. A recrys-
tallization from CH2Cl2/Et2O/hexane led to 27 (240 mg,
73%) as white crystals; Rf: 0.34 (MeOH/CH2Cl2, 5:95, v/
v); mp 99 C; IR (m cm1) 1692 (C@O carbamate), 1630
(C@O amide), 1584, 1505 (ArC@C); 1H NMR d 6.56 (s,
4H, ArH), 5.70–4.13 (m, 3H, piperazine), 4.04 (m, 2H,
CH2O), 3.91 (t, 2H, J = 6.64 Hz, CH2OPh), 3.80 (s,
15H, CH3O), 3.77–3.05 (m, 8H, NCH2CH3, piperazine),
1.66 (m, 2H, CH2), 1.39 (m, 2H, CH2), 0.98 (m, 6H,
NCH2CH3), 0.88 (t, 3H, J = 7.16 Hz, CH3);
13C NMR
d 170.84 (C@O amide), 155.09 (C@O carbamate),
153.58, 153.38, 139.46, 139.02, 130.11, 129.90, 104.56,
104.30 (ArC@C), 73.22 (PhOCH2), 60.92 (CH2O),
60.81, 56.24 (CH3O), 41.82, 41.12 (NCH2CH3), 32.03,
18.94 (CH2), 13.77, 13.38 (CH3). Anal. (C33H47N3O10)
C, H, N.
4.2.27. 2-N,N-Diethylaminocarbonyloxymethyl-1,4-di(3,4-
dimethoxybenzoyl)piperazine (29a). The same procedure
as described in Serradji et al.12 was followed to prepare
29a but using 3,4-dimethoxybenzoyl chloride and led to
3.35 g (53.2%) of 29a as white crystals; Rf: 0.49 (MeOH/
CH2Cl2, 5:95, v/v); mp 103.9 C; IR (m cm1) 1693
(C@O carbamate), 1622 (C@O amide), 1583 (ArC@C);
1H NMR d 6.95 (s, 2H, ArH-2), 6.92 and 6.79 (2d, 4H,
J = 8.01 Hz, ArH-5 andArH-6), 5.10–4.10 (m, 3H, piper-
azine), 4.03 (m, 2H, CH2O), 3.84 (br s, 12H, CH3O), 3.75–
2.70 (m, 8H, N(CH2CH3)2, piperazine), 1.13 (br s, 6H,
CH3);
13C NMR d 170.87, 170.71 (C@O amide), 154.98
(C@O carbamate), 150.44, 150.37, 148.95, 148.83,
127.06, 126.89, 120.04, 119.84, 110.25 (ArC@C), 60.75
(CH2O), 55.78 (CH3O), 41.68, 40.98 (NCH2CH3),
13.75, 13.25 (NCH2CH3). Anal. (C28H37N3O8) C, H, N.
4.2.28. 2-N,N-Diethylaminocarbonyloxymethyl-1,4-
di(2,4-dimethoxybenzoyl)piperazine (29b). The same pro-
cedure as in Serradji et al.12 was followed to prepare 29b
but using 2,4-dimethoxybenzoyl chloride and led to
960 mg (49%) of 29b as white crystals; Rf: 0.27 (MeOH/
CH2Cl2, 5:95, v/v);mp85 C ; IR (m cm1) 1708 (C@Ocar-
bamate), 1606 (C@O amide), 1600 (ArC@C); 1H NMR d
7.12 (m, 2H, ArH-3), 6.44 (m, 4H, ArH-5and ArH-6),
5.10–4.10 (m, 3H, piperazine), 4.02 (m, 2H, CH2O), 3.75
(br s, 12H, CH3O), 3.60–2.50 (m, 8H, N(CH2CH3)2,
piperazine), 1.09 (br s, 6H, CH3);
13H NMR d 168.39
(C@O amide), 161.78 (C@O carbamate), 156.46, 154.96,
129.63, 117.53, 104.94, 98.17 (ArC@C), 60.74 (CH2O),
55.33 (CH3O), 47.49, 43.10, 42.31 (piperazine), 41.68,
40.98 (NCH2CH3), 13.71, 13.35 (NCH2CH3). Anal.
(C28H37N3O8ÆH2O) C, H, N.
4.2.29. 2-N,N-Diethylaminocarbonyloxymethyl-1,4-di(4-
hydroxy-3,5-dimethoxybenzoyl)piperazine (29c). The
same procedure as for the preparation of the compound
20 was followed to prepare 29c and led to 1.46 g (37%)
of this compound as white crystals; Rf: 0.21 (MeOH/
CH2Cl2, 5:95, v/v); mp 140.1 C ; IR (m cm1) 3470 and
3191 (OH), 1700 (C@O carbamate), 1630 (C@O amide),
1591 (ArC@C); 1H NMR d 6.61 (s, 4H, ArH), 5.96 (br
s, 2H, OH), 5.20–3.99 (m, 5H, CH2O, piperazine), 3.81(s, 12H, CH3O), 3.30–2.50 (m, 8H, N(CH2CH3)2, pipera-
zine), 1.00 (m, 6H, CH3);
13C NMR d 171.03, 170.84
(C@O amide), 155.02 (C@O carbamate), 146.87, 136.64,
136.56, 125.45, 125.88, 104.52, 104.42 (ArC@C), 60.87
(CH2O), 56.32, 56.28 (CH3O), 41.66, 40.95 (NCH2CH3),
13.71, 12.25 (NCH2CH3). Anal. (C28H37N3O10Æ0.75H2O)
C, H, N.
4.2.30. 2-N,N-Diethylaminocarbonyloxymethyl-1,4-di-
benzoylpiperazine (29d).The same procedure as described
in Serradji et al.12 was followed to prepare 29d but using
benzoyl chloride and led to 600 mg (82%) of the title com-
pound as white crystals;Rf: 0.19 (MeOH/CH2Cl2, 2:98, v/
v);mp120.9 C; IR (m cm1) 1692 (C@Ocarbamate), 1627
(C@Oamide), 1577 (ArC@C); 1HNMR d 7.34 (br s, 10H,
ArH), 5.10–4.10 (m, 3H, piperazine), 4.04 (m, 2H,CH2O),
3.90–2.30 (m, 8H,N(CH2CH3)2, piperazine), 1.01 (m, 6H,
CH3);
13C NMR d 171.06 (C@O amide), 155.12 (C@O
carbamate), 135.08, 134.87, 130.02, 128.58, 128.53,
126.93 (ArC@C), 60.71 (CH2O), 55.78 (OCH3), 41.85,
41.16 (NCH2CH3), 13.88, 13.36 (NCH2CH3). Anal.
(C24H29N3O4) C, H, N.
4.2.31. 2-N,N-Diethylaminocarbonyloxymethyl-1,4-di-
(pyridin-4-ylcarbonyl)piperazine (29e). The same proce-
dure as described in Serradji et al.12 was followed to pre-
pare 29e but using isonicotinoyl chloride hydrochloride
and led to 460 mg (62.6%) of the title compound as white
crystals;Rf: 0.19 (MeOH/CH2Cl2, 5:95, v/v);mp135.5 C;
IR (m cm1) 1693 (C@O carbamate), 1628 (C@O amide),
1597 (ArC@C); 1HNMR d 8.64 (s, 4H, ArH), 7.22 (s, 4H,
ArH), 5.50–4.15 (m, 3H, CHOC@O, piperazine), 4.02
(dd, 1H, J = 6.03 and 11.06 Hz, CHOC@O), 3.98–2.30
(9H, N(CH2CH3)2, piperazine), 1.02 (m, 6H, CH3);
13C
NMR d 168.36 (C@O), 154.79 (C@O carbamate),
150.41, 142.41, 142.22, 120.99 (ArC@C), 60.38 (CH2O),
48.19, 46.90 (piperazine), 41.95, 41.17 (NCH2CH3),
13.86, 13.34 (CH3). Anal. (C22H27N5O4) C, H, N.
4.2.32. 2-N,N-Diethylaminocarbonyloxymethyl-1,4-di(3,4,
5-trimethoxybenzyl)piperazine, hydrochloride (30). The
same procedure as for the preparation of the compound
9 was followed to prepare 30 but using 3,4,5-trimethoxyb-
enzyl chloride and 28 and led to 1.48 g (74%) of the corre-
sponding free base, which (500 mg, 0.86 mmol) was
bubbled with HCl in EtOH and recrystallized from
EtOH/Et2O to provide 30 (430 mg, 77%) as a solid; Rf:
(MeOH/CH2Cl2, 1:99, v/v); mp 163.2 C; IR (m cm1)
1700 (C@O), 1598 (ArC@C); 1H NMR (DMSO-d6) d
11.80 (br s, 2H, NH+), 7.09 (s, 4H, ArH), 4.71–3.92 (m,
7H, CH2–Ph, CH2OC@O, piperazine), 3.79 (s, 12H,
CH3O), 3.66 (s, 6H, CH3O), 3.45 (m, 6H, CH2N
+), 3.22
(m, 4H, N(CH2CH3)2), 1.02 (m, 6H, CH3);
13C NMR
(DMSO-d6) d 153.88 (C@O carbamate), 152.85, 138.03,
137.89, 125.14, 124.40, 108.78 (ArC@C), 60.65 (CH2O),
59.93, 55.97 (CH3O), 41.51, 40.74 (NCH2CH3), 14.03,
13.26 (CH3). Anal. (C30H47N3Cl2O8Æ1.5H20) C, H, N.
4.2.33. 2-N,N-Diethylaminocarbonyloxymethyl-1,4-di(3,4,
5-trimethoxythiobenzoyl)piperazine (31). This compound
was prepared using the same procedure as for the com-
pound41but from 1a16 and31 (460 mg, 87%)wasobtained
as yellow crystals; Rf: 0.55 (MeOH/CH2Cl2, 5:95, v/v); mp
N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125 812395.1 C; IR (m cm1) 1700 (C@O), 1582 (ArC@C); 1H
NMR d 6.48 (br s, 4H, ArH), 6.01 (m, 1H, piperazine),
5.65 (m, 1H, piperazine), 4.45 (m, 1H, piperazine), 4.09
(m, 2H, CH2OC@O), 3.79 (s, 18H, CH3O), 3.65–2.05 (m,
8H, N(CH2CH3)2, piperazine), 1.05 and 0.81 (2m, 6H,
CH3);
13C NMR d 202.94, 202.64 (C@S), 154.93 (C@O),
153.28, 138.76, 137.71, 137.45, 103.33 (ArC@C), 61.07
(CH2O), 60.82, 56.24 (OCH3), 41.93, 41.29 (NCH2CH3),
14.08, 13.41 (CH3). Anal. (C30H41N3O8S2Æ0.5H2O)
C, H, N.
4.2.34. 3-N,N-Diethylaminocarbonyloxymethyl-1-diphe-
nylmethylpiperazine (32). The process was the same as
for the synthesis of 9 but using diphenylmethyl bromide
and led to 900 mg (45.4%) of 32;Rf: 0.15 (MeOH/CH2Cl2,
5:95, v/v); IR (m cm1) 3251 (NH), 2965 (ArCH), 1704
(C@O), 1592 (ArC@C); 1H NMR d 7.31 (m, 4H, ArH),
7.13 (m, 6H, ArH), 4.14 (s, 1H, CHPh2), 3.89 (m, 2H,
CH2O), 3.30–2.94 (m, 5H, NH, N(CH2CH3)2), 2.88 (m,
2H, piperazine), 2.80–2.55 (m, 2H, piperazine), 1.96 (m,
1H, piperazine), 1.78 (m, 2H, piperazine), 0.96 (m, 6H,
CH3);
13C NMR d 155.47 (C@O carbamate), 142.55,
142.41, 128.41, 127.82, 126.84 (ArC@C), 76.36 (CHPh2)
66.71 (CH2O), 54.93, 54.08, 52.56, 45.13 (piperazine),
41.68, 41.21 (NCH2CH3), 13.90, 13.51 (NCH2CH3).
4.2.35. 2-N,N-Diethylaminocarbonyloxymethyl-4-diphe-
nylmethyl-1-(3,4,5-trimethoxybenzoyl)piperazine, hydro-
chloride (33). This compound (700 mg, 48.5%) was
prepared as described for the compound 2 and ob-
tained as yellow crystals; Rf: 0.35 (MeOH/CH2Cl2,
3:97, v/v); mp 170.6 C; IR (m cm1) 1700 (C@O car-
bamate), 1648 (C@O amide), 1584 (ArC@C); 1H
NMR d 7.91 (br s, 4H, ArH), 7.30 (m, 6H, ArH),
6.64 (br s, 2H, ArH), 5.50-3.90 (m, 5H, CH2O,
CHPh2, piperazine), 3.76 (s, 9H, CH3O), 3.60–1.90
(m, 9H, N(CH2CH3)2, piperazine), 0.91 (m, 6H,
CH3);
13C NMR d 170.28 (C@O amide), 154.73
(C@O carbamate), 153.19, 139.63, 134.27, 133.33,
129.58, 129.45, 129.20, 129.04, 128.44, 104.49
(ArC@C), 78.87 (CHPh2), 62.17 (CH2O), 60.63, 56.18
(CH3O), 51.91, 51.32, 41.67, 41.00 (NCH2CH3,pipera-
zine), 13.85, 13.19 (NCH2CH3). Anal. (C33H42N3ClO6)
C, H, N.
4.2.36. 3-N,N-Diethylaminocarbonyloxymethyl-1-triphe-
nylmethylpiperazine (34). To a solution of 2816 (6.26 g,
21.73 mmol) and Et3N (12 mL, 86.92 mmol) in CH2Cl2
(100 mL) was added dropwise a solution of triphenylm-
ethyl chloride (6 g, 21.73 mmol) in CH2Cl2 (100 mL).
The solution was stirred for 6 h and then washed with
saturated NaHCO3 solution and water to neutral pH,
dried (MgSO4) and the solvent evaporated. The residue
(9.9 g, 99.7%) was used in the next step without any fur-
ther puriﬁcation; Rf: 0.093 (MeOH/CH2Cl2, 3:97, v/v);
IR (m cm1) 3320 (NH), 3045 (ArCH), 1695 (C@O car-
bamate), 1595 (ArC@C); 1H NMR d 7.40 (m, 6H, ArH),
7.10 (m, 9H, ArH), 3.86 (m, 2H, CH2O), 3.50–2.45 (m,
7H, CH2CH3, piperazine), 2.00–1.10 (m, 4H, piperazine),
0.97 (m, 6H, CH3);
13C NMR d 155.46 (C@O), 129.26,
127.40, 125.91 (ArC@C), 66.85 (CH2O), 54.68, 51.50,
48.78, 45.75 (piperazine), 41.67, 41.21 (NCH2CH3),
13.93, 13.45 (NCH2CH3).4.2.37. 2-N,N-Diethylaminocarbonyloxymethyl-1-(4-hy-
droxy-3,5-dimethoxybenzoyl)-4-triphenylmethylpiperazine
(35). This compound was prepared from 34 using the
same procedure as for the preparation of 20 and 2.2 g
(52.4%) of 35 was obtained; Rf: 0.30 (MeOH/CH2Cl2,
5:95, v/v); IR (m cm1) 3391 (OH), 1679 (C@O carba-
mate), 1620 (C@O amide), 1606 (ArC@C); 1H NMR d
7.38 (m, 6H, ArH), 7.16 (m, 9H, ArH), 6.53 (s, 2H,
ArH), 5.61 (br s, 1H, OH), 5.22 (br s, 1H, CHOC@O),
4.98 (br s, 1H, CHOC@O), 4.40 (br s, 1H, piperazine),
3.78 (s, 6H, CH3O), 3.46–2.81 (m, 8H, N(CH2CH3)2,




(36). A mixture of 35 (950 mg, 1.49 mmol), 1-bromobu-
tane (340 lL, 2.98 mmol) and K2CO3 (411 mg, 2.98
mmol) in dry acetone (25 mL) was reﬂuxed for 6 h. After
ﬁltration of the salts and evaporation of the solvent, the
residue was taken in CH2Cl2, washed with water, dried
(MgSO4), ﬁltered and the solvent eliminated in vacuum.
A column chromatography through silica gel using
MeOH/CH2Cl2 (0.5:99.5, v/v) as eluent yielded 850 mg
(82.3%) of the title compound as a wax; Rf: 0.36
(MeOH/CH2Cl2, 2:98, v/v); IR (m cm
1) 1694 (C@O car-
bamate), 1638 (C@O amide), 1579 (ArC@C); 1H NMR
d 7.34 (br s, 6H, ArH), 7.18–7.04 (m, 9H, ArH), 6.45 (s,
2H, ArH), 5.21 (br s, 1H, CHOC@O), 4.96 (br s, 1H,
CHOC@O), 4.42 (br s, 1H, piperazine), 3.84 (t, 2H,
J = 6.65 Hz, Ph–OCH2), 3.68 (s, 6H, CH3O), 3.60–2.70
(m, 8H, N(CH2CH3)2, piperazine), 1.74 (m, 2H, pipera-
zine), 1.59 (qt, 2H, J = 6.99 Hz, Ph–OCH2CH2CH2CH3),
1.38 (sex, 2H, J = 7.46 Hz, Ph–OCH2CH2CH2CH3), 1.05
(t, 3H, J = 6.56 Hz, CH3), 1.02 (m, 3H, CH3), 0.82 (t, 3H,
J = 7.30 Hz, CH3);
13C NMR d 169.96 (C@O amide),
155.62 (C@O carbamate), 153.08, 152.06, 138.27,
130.36, 129.03, 127.39, 126.06, 104.36 (ArC@C), 76,68
(CPh3), 72.84 (CH2OPh), 62.70 (CH2O carbamate),
55.89 (CH3O), 48.87, 47.90, 44.87 (CH2 piperazine),
41.55, 40.99 (NCH2CH3), 31.77, 18.71 (OCH2 (CH2)2C
H3), 13.76, 13.54, 13.30 (NCH2CH3 and OCH2(CH2)2
CH3).
4.2.39. 1-(4-Butoxy-3,5-dimethoxybenzoyl)-2-N,N-dieth-
ylaminocarbonyloxymethylpiperazine (37). This com-
pound was prepared from 36 using the same procedure
as for 40 and 340 mg (62%) of 37 was obtained; Rf: 0.13
(MeOH/CH2Cl2, 5:95, v/v); IR (m cm
1) 3325 (NH),
1676 (C@O carbamate), 1625 (C@O amide), 1577
(ArC@C); 1H NMR d 6.54 (s, 2H, ArH), 5.15–4.10 (m,
4H, CH2OC@O, NH, piperazine), 3.89 (t, 2H, J =
6.71 Hz, Ph–OCH2), 3.76 (s, 6H, CH3O), 3.70–2.4 (m,
10H, N(CH2CH3)2, piperazine), 1.65 (qt, 2H, J =
6.96 Hz, PhOCH2CH2CH2CH3), 1.39 (sex, 2H, J =
7.31 Hz, PhOCH2CH2CH2 CH3), 1.01 (t, 6H, J =
7.03 Hz, CH3), 0.87 (t, 3H, J = 7.25 Hz, CH3).
4.2.40. 4-Benzyl-1-(4-butoxy-3,5-dimethoxybenzoyl)-2-
N,N-diethylaminocarbonyloxymethylpiperazine, hydro-
chloride (38).This compound was prepared from 37 using
the same procedure as for the preparation of 3. A chlorhy-
dratation using HCl and a recrystallization fromMeOH/
8124 N. Serradji et al. / Bioorg. Med. Chem. 14 (2006) 8109–8125Et2O gave 200 mg (36.6%) of the title compound;Rf: (free
base) 0.22 (MeOH/CH2Cl2, 2:98, v/v); mp 143.8 C; IR (m
cm1) 1700 (C@O carbamate), 1647 (C@O amide), 1582
(ArC@C); 1H NMR d 11.10 (br s, 1H, NH+), 7.62 (m,
2H, ArH), 7.46 (m, 3H, ArH), 6.67 (s, 2H, ArH), 5.40–
4.09 (m, 5H, CH2OC@O, piperazine), 3.86 (t, 2H,
J = 6.30 Hz, PhOCH2), 3.78 (s, 6H, CH3O), 3.30–2.90
(m, 8H, N(CH2CH3)2, piperazine), 1.59 (qt, 2H, J =
6.70 Hz, PhOCH2CH2CH2CH3), 1.42 (sex, 2H, J =
7.10 Hz, PhOCH2CH2CH2CH3), 0.90 (t, 9H, J =
7.17 Hz, CH3);
13C NMR d 169.90 (C@O amide),
155.10 (C@O carbamate), 153.45, 138.44, 131.92,
129.50, 128.70, 104.62 (ArC@C), 72.07 (CH2OAr),
60.95 (CH2O carbamate), 56.08 (CH3O), 50.87
(CH2Ph), 41.19, 40.74 (NCH2CH3), 31.66, 18.56
(–OCH2(CH2)2 CH3), 13.64, 13.34 (CH3). Anal.
(C30H44N3ClO6) C, H, N.
4.2.41. 2-N,N-Diethylaminocarbonyloxymethyl-1-(3,4,5-
trimethoxybenzoyl)-4-triphenylmethylpiperazine (39).
Compound 39 was prepared from 34 as described for
the compound 2 but at room temperature. A silica gel col-
umn using CH2Cl2as eluent yielded 39 (9.52 g, 89%) as a
wax; Rf: 0.33 (MeOH/CH2Cl2, 3:97, v/v); IR (m cm
1)
1701 (C@O carbamate), 1616 (C@O amide), 1507
(ArC@C); 1H NMR d 7.38 and 7.19 (2m, 15H, ArH),
6.49 (s, 2H, ArCH), 4.99 and 4.41 (2m, 2H, piperazine),
3.83 (m, 2H, CH2O), 3.74 and 3.73 (2s, 9H, CH3O), 3.59
(q, 2H, J = 7.01 Hz, NCH2CH3), 3.60–2.60 (m, 6H,
NCH2CH3, piperazine), 1.79 (m, 1H, piperazine), 1.09
(m, 6H, CH3);
13C NMR 169.97 (C@O amide), 155.78
(C@O carbamate), 152.96, 138.96, 130.86, 129.13,
127.53, 126.20, 104.31 (ArC@C), 62.83 (CH2O), 60.66,
56.02 (OCH3), 49.25, 48.97, 48.00, 44.93 (piperazine),
41.69, 41.12 (NCH2CH3), 13.90, 13.43 (NCH2CH3).
4.2.42. 2-N,N-Diethylaminocarbonyloxymethyl-1-(3,4,5-
trimethoxybenzoyl)piperazine (40). To a solution of 39
(6.5 g, 9.98 mmol) in MeOH (100 mL) was added drop-
wise HCl 12 N (6 mL). This solution was stirred for
10 min at room temperature and the solvent removed
in vacuum. The residue was then taken up with CH2Cl2,
washed with saturated NaHCO3 solution and water,
dried (MgSO4), ﬁltered and evaporated. A silica gel col-
umn using MeOH/CH2Cl2as eluent (3:97, v/v) yielded 40
(3.8 g, 93%) as a wax; Rf: 0.11 (MeOH/CH2Cl2, 3:97, v/
v); IR (m cm1) 3330 (NH), 1693 (C@O carbamate),
1632 (C@O amide), 1584 (ArC@C); 1H NMR d 6.55
(s, 2H, ArH), 4.90–4.40 (m, 2H, piperazine), 4.29 (m,
2H, CH2O), 3.79 and 3.77 (2s, 9H, CH3O), 3.40–2.50
(m, 9H, N(CH2CH3)2, piperazine), 1.37 (br s, 1H,
NH), 1.02 (t, 6H, J = 7 Hz, CH3);
13C NMR d 170.44
(C@O amide), 155.36 (C@O carbamate), 153.07,
138.95, 130.94, 104.08 (ArC@C), 61.44 (CH2O), 60.62,
56.10 (OCH3), 45.86 (piperazine), 41.67, 41.07
(NCH2CH3), 13.88, 13.25 (NCH2CH3).
4.2.43. 2-N,N-Diethylaminocarbonyloxymethyl-1-(3,4,5-
trimethoxythiobenzoyl)piperazine (41). To a cooled (ice
bath) solution of 40 (1.41 g, 3.44 mmol) in THF
(30 mL) was added portionwise Lawesson’s reagent
(1.4 g, 3.44 mmol). The mixture was stirred for 30 min
at 0 C and then overnight at room temperature.The solvent was removed in vacuum and a chromatog-
raphy using MeOH/CH2Cl2 (1/99, v/v) as eluent yielded
41 (1.2 g, 82%) as a wax; Rf: 0.18 (MeOH/CH2Cl2, 5:95,




perazine (42).Compound 42was prepared from the com-
pound 41, as described for the compound 2, and obtained
as a pale yellow solid (405 mg, 23.2 %): Rf: 0.44 (MeOH/
CH2Cl2, 5:95, v/v); mp 175 C; IR (m cm1) 1699 (C@O
carbamate), 1642 (C@O amide), 1588 (ArC@C); 1H
NMR d 6.58 (s, 2H, ArH), 6.47 (m, 2H, ArH), 5.10–4.00
(m, 5H, CH2O, piperazine), 3.78 (s, 18H, CH3O), 3.70–
2.60 (m, 8H, N(CH2CH3)2, piperazine), 1.04 (m, 6H,
CH3);
13C NMR d 202.53 (C@S), 170.66 (C@O amide),
155.04 (C@O carbamate), 153.26, 153.07, 139.41,
138.41, 137.76, 129.60, 104.22 (ArC@C), 60.91 (CH2O),
60.82, 56.12, 56.04 (OCH3), 54.81, 47.65 (piperazine),
41.72, 41.10 (NCH2CH3), 13.90, 13.27 (NCH2CH3).
Anal. (C30H41N3O9S) C, H, N.
4.2.45. Computational tools.All the calculations were per-
formed with the Gaussian 98program26 on a SGI Origin
3800. All the selected conformations were fully optimized
within RHF molecular orbital formalism, using the 6-
31G basis set.27 The 3D electrostatic potential has also
been computed at that level with the same basis set.
4.3. Biological methods
4.3.1. Platelet aggregation. The inhibition of platelet
aggregation was conducted according to the published
procedures.12 Brieﬂy, it was determined using platelet-
rich plasma (PRP) of New Zealand rabbits by the meth-
od of Cazenave et al.29 Blood samples were collected
from auricular artery into a citrate buﬀer (3.8%, pH
7.4), and PRP was obtained by centrifugation for
15 min at 1200 rpm. The antagonists were solubilized
in DMSO at concentrations from 102 to 107 M and
added to the incubated and stirred PRP for 2 min before
PAF (2.5 nM) challenge. Platelet aggregation induced
by PAF in the presence of the antagonists was moni-
tored by continuous recording of light transmission in
a dual-channel recorder (Cronolog Coultronics Appara-
tus) and was compared to a control aggregation induced
by PAF alone. The drug concentration required to pro-
duce 50% inhibition (IC50) was calculated from dose–
response curves (number of determinations: 5–6).
4.3.2. Antiviral assay. All experiments were performed in
triplicate in cells isolated from one blood donor. Antiviral
assays and data analysis were conducted according to the
published procedures.12–14 HIV-1 replication was as-
sessed in cell culture supernatants by quantifying reverse
transcriptase (RT), using the RetroSys kit (Innovagen).Acknowledgments
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